2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Mazyar Shadman, MD, MPH, discusses the exploration of MB-106, a third-generation CD20-targeted autologous CAR T-cell therapy, in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia.
Mazyar Shadman, MD, MPH, physician, Seattle Cancer Care Alliance, associate professor, Division of Medical Oncology, University of Washington School of Medicine, associate professor, Clinical Research Division, Fred Hutchinson Cancer Research Center, discusses the exploration of MB-106, a third-generation CD20-targeted autologous CAR T-cell therapy, in relapsed/refractory B-cell non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL).
A phase 1/2 trial (NCT03277729) is evaluating the efficacy and safety of MB-106 in patients with relapsed/refractory B-cell NHLs.
Though CD19-targeted CAR T-cell therapies are approved in various lymphomas, the development of a CD20-targeted CAR T-cell therapy could address other unmet needs for patients with B-cell NHLs, Shadman says. Some patients who receive an approved CD19-targeted CAR T-cell therapy can relapse after an initial response, and some histologies, such as CLL, do not have a currently approved CAR T-cell therapy, Shadman explains.
Since the threshold for acceptable toxicities in CLL and low-grade lymphomas is low, there is a need to develop a CAR T-cell therapy that delivers efficacy with manageable adverse effects, Shadman continues. MB-106 could represent an effective treatment option that is well tolerated for patients with low-grade or indolent lymphomas, Shadman concludes.